Spotlight on HDL-raising therapies: insights from the torcetrapib trials (Q37145837)

18 August 2017

1 reference

title

Spotlight on HDL-raising therapies: insights from the torcetrapib trials (English)

1 reference

18 August 2017

Anatol Kontush

1

1 reference

PubMed ID

18431367

18 August 2017

Maryse Guérin

series ordinal

2

1 reference

PubMed ID

18431367

18 August 2017

M John Chapman

series ordinal

3

1 reference

18 August 2017

22 April 2008

1 reference

Nature Clinical Practice Cardiovascular Medicine

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

6

1 reference

18 August 2017

329-336

1 reference

Atherogenesis: a postprandial phenomenon

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Increasing apoA-I production as a target for CHD risk reduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

The paradox of dysfunctional high-density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Potential clinical utility of high-density lipoprotein-mimetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

New insights into the regulation of HDL metabolism and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Illuminating HDL--is it still a viable therapeutic target?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

The Yin and Yang of high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Pediatric cardiology in Italy today.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Why is HDL functionally deficient in type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1191

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO1191

1 reference

18 August 2017

1 reference

PubMed ID

18431367